Antonarakis, E S
Armstrong, A J
Dehm, S M
Luo, J
Article History
Received: 11 February 2016
Revised: 6 April 2016
Accepted: 7 April 2016
First Online: 17 May 2016
Competing interests
: ESA has served as a paid consultant/advisor for Janssen, Astellas, Sanofi, Dendreon, Essa, and Medivation; has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Exelixis, Genentech, Novartis and Tokai; and is a co-inventor of a technology that has been licensed to Tokai. AJA has served as a paid consultant for Sanofi-aventis, Dendreon, Janssen, Eisai, Bayer and Medivation/Astellas; is on the speaker’s bureau for Sanofi-aventis and Dendreon; and receives research funding to his institution from Janssen, Medivation/Astellas, Sanofi-aventis, Active Biotech, Bayer, Dendreon, Novartis and Pfizer. SMD has served as a paid consultant/advisor for Medivation/Astellas. JL has served as a paid consultant/advisor for Astellas, Gilead and Sanofi; has received research funding to his institution from Orion, Mirati, Astellas, Sanofi and Gilead; and is a co-inventor of a technology that has been licensed to A&G and Tokai.